Iovance Biotherapeutics/$IOVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Iovance Biotherapeutics
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Ticker
$IOVA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
838
ISIN
US4622601007
Website
IOVA Metrics
BasicAdvanced
$748M
-
-$1.23
1.06
-
Price and volume
Market cap
$748M
Beta
1.06
52-week high
$12.50
52-week low
$1.64
Average daily volume
17M
Financial strength
Current ratio
4.178
Quick ratio
3.51
Long term debt to equity
5.759
Total debt to equity
6.996
Management effectiveness
Return on assets (TTM)
-27.14%
Return on equity (TTM)
-51.85%
Valuation
Price to revenue (TTM)
3.202
Price to book
0.97
Price to tangible book (TTM)
1.55
Price to free cash flow (TTM)
-1.96
Growth
Revenue change (TTM)
11,070.12%
Earnings per share change (TTM)
-31.83%
3-year earnings per share growth (CAGR)
-18.73%
What the Analysts think about IOVA
Analyst ratings (Buy, Hold, Sell) for Iovance Biotherapeutics stock.
Bulls say / Bears say
Iovance Biotherapeutics' recent FDA approval of Amtagvi, the first T cell therapy for solid tumors, positions the company as a pioneer in the oncology space, potentially driving significant revenue growth. (nasdaq.com)
The company's robust cash position, with approximately $449.6 million as of July 24, 2024, is expected to fund operations until 2026, providing a solid foundation for ongoing research and development. (investing.com)
Analysts maintain a positive outlook on Iovance, with Baird reaffirming an 'Outperform' rating and a $24.00 price target, reflecting confidence in the company's strategic direction and financial health. (investing.com)
Despite the FDA approval of Amtagvi, initial sales have been underwhelming, with only $12.8 million reported in Q2 2024, falling short of the anticipated $20 to $25 million. (investing.com)
Piper Sandler downgraded Iovance to 'Neutral' from 'Overweight' and slashed the price target to $10 from $19, citing a slow launch of Amtagvi and concerns over patient infusion rates. (nasdaq.com)
The company reported a net loss of $97.1 million for Q2 2024, highlighting ongoing financial challenges despite recent product launches. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 16 May 2025.
IOVA Financial Performance
Revenues and expenses
IOVA Earnings Performance
Company profitability
IOVA News
AllArticlesVideos
Levi & Korsinsky Urges Iovance Biotherapeutics, Inc. (IOVA) Shareholders to Act Before Lead Plaintiff Deadline July 14, 2025
Accesswire·8 hours ago
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA
Accesswire·8 hours ago
IOVA ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Iovance Biotherapeutics, Inc. - July 14, 2025 Deadline
Accesswire·12 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Iovance Biotherapeutics stock?
Iovance Biotherapeutics (IOVA) has a market cap of $748M as of June 13, 2025.
What is the P/E ratio for Iovance Biotherapeutics stock?
The price to earnings (P/E) ratio for Iovance Biotherapeutics (IOVA) stock is 0 as of June 13, 2025.
Does Iovance Biotherapeutics stock pay dividends?
No, Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders as of June 13, 2025.
When is the next Iovance Biotherapeutics dividend payment date?
Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Iovance Biotherapeutics?
Iovance Biotherapeutics (IOVA) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.